Cognition Therapeutics Inc (CGTX)

$0.44 0.00 (-0.82%)
Market Cap 21.95M
Revenue (ttm) 0.00
Net Income (ttm) -33.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 427,100
Avg Vol 1,481,754
Day's Range N/A - N/A
Shares Out 61.97M
Stochastic %K 88%
Beta 1.01
Analysts Strong Sell
Price Target $5.40

Latest News on CGTX

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Apr 1, 2025, 7:30 AM EDT - 26 days ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 25, 2025, 7:30 AM EDT - 4 weeks ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 1:15 PM EDT - 5 weeks ago

Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 20, 2025, 7:00 AM EDT - 5 weeks ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 13, 2025, 4:05 PM EDT - 6 weeks ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 12, 2025, 4:05 PM EDT - 6 weeks ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Mar 10, 2025, 7:30 AM EDT - 6 weeks ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 27, 2025, 7:30 AM EST - 2 months ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Feb 25, 2025, 7:30 AM EST - 2 months ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 30, 2025, 7:30 AM EST - 3 months ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Jan 8, 2025, 4:14 PM EST - 3 months ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Dec 18, 2024, 11:06 AM EST - 4 months ago

Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Dec 18, 2024, 7:22 AM EST - 4 months ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 5 months ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 25, 2024, 7:30 AM EST - 5 months ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 13, 2024, 7:30 AM EST - 5 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Nov 12, 2024, 7:30 AM EST - 5 months ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 31, 2024, 4:15 PM EDT - 6 months ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 29, 2024, 12:55 PM EDT - 6 months ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 23, 2024, 7:30 AM EDT - 6 months ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 22, 2024, 7:30 AM EDT - 6 months ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 2, 2024, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Oct 1, 2024, 7:30 AM EDT - 7 months ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 8 months ago

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Aug 22, 2024, 7:31 AM EDT - 8 months ago

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Aug 11, 2024, 12:55 AM EDT - 9 months ago

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Aug 8, 2024, 7:00 AM EDT - 9 months ago

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Aug 5, 2024, 7:30 AM EDT - 9 months ago

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Jul 29, 2024, 7:14 AM EDT - 9 months ago

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's disease

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

Jul 29, 2024, 7:00 AM EDT - 9 months ago

Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

Jul 26, 2024, 4:11 PM EDT - 9 months ago

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Jul 2, 2024, 7:30 AM EDT - 10 months ago

Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

May 21, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

May 7, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

Apr 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

Cognition Therapeutics, Inc. (CGTX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 12:02 PM EDT - 1 year ago

Cognition Therapeutics, Inc. (CGTX) Q4 2023 Earnings Call Transcript

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Mar 15, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

Mar 11, 2024, 8:16 PM EDT - 1 year ago

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies

Mar 6, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

Feb 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

Feb 6, 2024, 8:47 AM EST - 1 year ago

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

Cognition Therapeutics CEO Issues Letter to Shareholders

Jan 4, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

Nov 16, 2023, 7:30 AM EST - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases

Nov 15, 2023, 7:30 AM EST - 1 year ago

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases